GlassScriptPhysician profile
Stephanie Ford
NPI 1841765187
$1,102.39
in general payments reported to CMS, 2019-2025
20 companies · $287 in 2025
The $287 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $84.76 · 2022: $185 · 2023: $290 · 2024: $255 · 2025: $287.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $832.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $832.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $207.53 | 2021-2025 | Wegovy, Rybelsus, Ozempic |
| Lilly USA, LLC | $188.36 | 2021-2025 | Mounjaro, Zepbound |
| Exact Sciences Corporation | $146.66 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Abbvie INC. | $111.75 | 2023-2025 | |
| Glaxosmithkline, LLC. | $95.70 | 2021-2025 | Trelegy Ellipta |
| Teva Pharmaceuticals USA, INC. | $87.39 | 2024-2025 | Austedo Xr, Austedo Xr |
| Biohaven Pharmaceuticals, INC. | $37.95 | 2021 | |
| Sumitomo Pharma America, INC. | $36.13 | 2023 | Gemtesa |
| Biohaven Pharmaceutical Holding Company LTD. | $20.03 | 2022 | |
| Merck Sharp & Dohme LLC | $18.06 | 2022 | |
| Amgen INC. | $17.86 | 2023 | Repatha, Otezla |
| Pfizer INC. | $17.49 | 2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $16.76 | 2025 | Xifaxan |
| Boston Scientific Corporation | $16.55 | 2025 | Watchman Flx |
| Cipher Pharmaceuticals US LLC | $15.91 | 2025 | Spinosad, Natroba |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $14.76 | 2024 | Voquezna |
| Shield Therapeutics INC | $13.63 | 2023 | Accrufer |
| Otsuka America Pharmaceutical, INC. | $13.52 | 2024 | Rexulti |
| Mylan Specialty L.P. | $13.35 | 2024 | Yupelri |
| Novartis Pharmaceuticals Corporation | $13.00 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephanie Ford listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.